PeterMVoorheesMD

Hematologic Oncology

Professor of Medicine, Department of Hematologic Oncology and Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute, Atrium Health

Join to view full profile

Dr. Voorhees is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Voorhees' full profile

Already have an account?

Office
1021 Morehead Medical Dr
Charlotte, NC 28204
Phone+1 980-442-5219

Fax+1 980-442-5241
Is this information wrong?

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1997 - 2001
University of Michigan Medical SchoolClass of 1997

Certifications & Licensure

NC State Medical License 2001 - 2024
WI State Medical License 1998 - 2001
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Top MD Consumers Checkbook

Clinical Trials

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy Start of enrollment: 2008 Aug 01
Completed
Phase 2
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 Apr 01
Withdrawn
Phase 2
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma Start of enrollment: 2012 Jul 12
Completed
Phase 1
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Unknown status
Phase 1, Phase 2
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Start of enrollment: 2009 Apr 21
Terminated
Phase 2
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2014 Feb 01
Active, not recruiting
Phase 1, Phase 2
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML Start of enrollment: 2021 Jul 12
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...
Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson Jr, Nitya Nathwa...> ;American Journal of Hematology. 2024 Apr 15
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Aimaz Afrough, Hamza Hashmi, Doris K Hansen, Surbhi Sidana, Chul Ahn, Lauren C Peres, Danai Dima, Ciara L Freeman, Omar Castaneda Puglianini, Mehmet H Kocoglu, Shebli ...> ;Blood Cancer Journal. 2024 Apr 12
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Bad...> ;British Journal of Haematology. 2024 Mar 19
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
Myra Robinson, Kristen Cassetta, Shanice Borden, Manisha Bhutani, Hamid Ehsan, Peter M Voorhees, Shebli Atrash, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry ...> ;Life. 2024 Mar 14
1 citations
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Lauren C Peres, Laura B Oswald, Christen M Dillard, Gabriel De Avila, Taiga Nishihori, Brandon J Blue, Ciara L Freeman, Frederick L Locke, Melissa Alsina, Omar Castane...> ;Blood Advances. 2024 Jan 9
4 citations
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Surbhi Sidana, Lauren C Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W Sborov...> ;Haematologica. 2024 Mar 1
1 citations
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
Rakesh Popat, Sagar Lonial, Peter M Voorhees, Simona Degli Esposti, Boris Gorsh, Ira Gupta, Joanna Opalinska, Sandhya Sapra, Trisha Piontek, Zangdong He, David Kleinma...> ;Journal of the Advanced Practitioner in Oncology. 2023 Sep 1
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Paul G Richardson, Brian G Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P Laubach, ...> ;Haematologica. 2023 Nov 1
12 citations
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Christopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, Leyla O Shune, Joseph P McGuirk, Douglas W Sborov, Charlotte B Wagner, M Hakan Kocoglu, Aaron Rapoport, ...> ;Blood Cancer Journal. 2023 Aug 9
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
Shebli Atrash, Myra Robinson, Alankrita Taneja, Barry Paul, Kristen Cassetta, Ami Ndiaye, Cindy Varga, Jared Block, Edward H Lipford, Elton T Smith, Chad M McCall, Vir...> ;European Journal of Haematology. 2023 Sep 1
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
Manisha Bhutani, David M Foureau, Myra Robinson, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Barry Paul, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, Katherine Rig...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jul 1
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the G...
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Badro...> ;Future Oncology. 2022 Dec 1
2 citations
Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study).
Hamid Ehsan, Alec Britt, Peter M Voorhees, Barry Paul, Manisha Bhutani, Cindy Varga, Zane Chiad, Brittany K Ragon, Al-Ola A Abdallah, Nausheen Ahmed, Shebli Atrash> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Apr 1
51 citations
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Doris K Hansen, Surbhi Sidana, Lauren C Peres, Christelle Colin Leitzinger, Leyla Shune, Alexandria Shrewsbury, Rebecca Gonzalez, Douglas W Sborov, Charlotte Wagner, D...> ;Journal of Clinical Oncology. 2023 Apr 10
6 citations
Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
David M Foureau, Barry A Paul, Fei Guo, Edward H Lipford, Kateryna Fesenkova, Elise Tjaden, Kendra Drummond, Manisha Bhutani, Shebli Atrash, Ami Ndiaye, Cindy Varga, P...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
13 citations
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER ...
Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, ...> ;Transplantation and Cellular Therapy. 2023 Mar 1
8 citations
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A Efebera, Cesar Rodriguez, Luciano J Costa, Ajai Chari, Rebecca Silbermann, Sarah A Holstein,...> ;British Journal of Haematology. 2022 Nov 1
34 citations
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Mye...
Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M Voorhees, Katja Weisel, Orlando F Bueno, Rajvineeth K Pothacamury, Kevin J Freise, Susan Yue, Jeremy A Ross, Akshant...> ;Journal of Clinical Oncology. 2022 Nov 1
4 citations
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Badro...> ;Blood Cancer Journal. 2022 Apr 13
14 citations
A phase I/II study of ixazomib, pomalidomide and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma. (Alliance A061202)
Peter M. Voorhees, Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera, Flora Mulkey, Misty Bova-Solem, Katelyn Santo, Destin Carlisle,...> ;American Journal of Hematology. 2021 Sep 24
7 citations
Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
David M. Foureau, Manisha Bhutani, Fei Guo, Katherine Rigby, Marina Leonidas, Elise Tjaden, Andee N. Fox, Shebli Atrash, Barry Paul, Peter M. Voorhees, Saad Z. Usmani> ;Cancer Medicine. 2021 Sep 8
2 citations
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
Peter M. Voorhees, Andrzej Jakubowiak, Shaji Kumar, Bindu Kanapuru, Andrea C. Baines, Vishal Bhatnagar, Rachel Ershler, Marc R. Theoret, Nicole J. Gormley, R. Pazdur> ;Clinical Cancer Research. 2021 Jul 27
82 citations
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al-Ola Abdallah, Natalie S. Callander, Douglas W. Sborov, Attaya Suvannasankha, Ka...> ;Cancer. 2021 Jul 27
2 citations
Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation.
Srinivasa R. Sanikommu, Emily S. Reese, Jiaxian He, Carlos Lee, Jing Ai, Candace Butler, Ryan Jacobs, Bei Hu, Shebli Atrash, Jigar Trivedi, Manisha Bhutani, Peter M. V...> ;Journal of Clinical Apheresis. 2021 Mar 12
9 citations
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Issam Hamadeh, Donald C Moore, Allison Martin, Allison Karabinos, Hailey Hill, Ami Ndiaye, Jordan Robinson, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhe...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Mar 4
Join now to see all

Journal Articles

International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood

Abstracts/Posters

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Result...
Peter M. Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

ATLAS Trial: Risk-Adapted Triplet Maintenance Therapy May Benefit Some Patients with Multiple MyelomaAugust 1st, 2022
Frontline Therapy for Multiple MyelomaMay 3rd, 2022
International Myeloma Foundation Launches "M-power Charlotte" to Improve Outcomes in Multiple Myeloma, a Cancer That Disproportionately Affects African AmericansMarch 11th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Atrium Health's Carolinas Medical CenterCharlotte, North Carolina